<div id="readability-page-1"><article><div id="ps-bar">See more from StockTitan in Google Search and AI answers.Adds StockTitan as a preferred source · opens GoogleAdd on Google</div>BRISBANE, Calif., June 05, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on June 2, 2026, the Compensation Committee of the Board of Directors (Compensation Committee) of Vera Therapeutics granted inducement awards consisting of non-qualified stock options to purchase 28,800 shares of Class A common stock and restricted stock units (RSUs) underlying 14,150 shares of Class A common stock to ten (10) new employees under the Vera Therapeutics, Inc. 2024 Inducement Plan (Inducement Plan). The Compensation Committee approved the awards as an inducement material to the new employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option granted on June 2, 2026 has an exercise price per share equal to $31.26, Vera Therapeutics’ closing trading price on June 2, 2026. Each stock option will vest over four years, with 25% of the underlying shares vesting on the first anniversary of the applicable vesting commencement date and the balance of the underlying shares vesting monthly thereafter over 36 months, subject to the new employee’s continued service relationship with Vera Therapeutics through the applicable vesting dates. Each of the RSU awards will vest over four years, with 25% of the underlying shares vesting on each anniversary of either May 20 or August 20, 2026, depending on the start date of the new employee, subject to the new employee’s continued service relationship with Vera Therapeutics through the applicable vesting dates. The awards are subject to the terms and conditions of the Inducement Plan and the terms and conditions of an applicable award agreement covering the grant. About Vera Therapeutics Vera Therapeutics is a biotechnology company focused on developing treatments for serious immunological diseases. Vera Therapeutics’ mission is to advance treatments that target the source of disease in order to change the standard of care for patients. Vera Therapeutics’ lead product candidate is atacicept, a fusion protein self-administered at home as a subcutaneous once weekly injection that blocks both B-cell Activating Factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL), which stimulate B cells to produce autoantibodies contributing to certain autoimmune diseases, including immunoglobulin A nephropathy (IgAN) and lupus nephritis. Beyond IgAN, Vera Therapeutics is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove clinically meaningful. In addition, Vera Therapeutics holds an exclusive license agreement with Stanford University for a novel, next generation fusion protein targeting BAFF and APRIL, known as VT-109, with wide therapeutic potential across the spectrum of B-cell-mediated diseases. Vera Therapeutics is also evaluating development of MAU868, a monoclonal antibody designed to neutralize infection with BK virus, which can have devastating consequences in kidney transplant recipients. Vera Therapeutics retains all global developmental and commercial rights to atacicept, VT-109 and MAU868. For more information, please visit www.veratx.com. For more information, please contact: Investor Contact: Joyce Allaire LifeSci Advisors 212-915-2569 jallaire@lifesciadvisors.com Media Contact: Debra Charlesworth Vera Therapeutics 415-854-8051 corporatecommunications@veratx.com <img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1Rjek1qUTRNU00zTmpNNE5ESTRJekl5TURjME5qaz0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1Rjek1qUTRNU00zTmpNNE5ESTRJekl5TURjME5qaz0"/> <img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/NTlkMmJmNmMtYTA3NC00Y2VmLThkN2EtODY5NjljOWQxNDAxLTEyMTkwMjItMjAyNi0wNi0wNS1lbg==/tiny/Vera-Therapeutics.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/NTlkMmJmNmMtYTA3NC00Y2VmLThkN2EtODY5NjljOWQxNDAxLTEyMTkwMjItMjAyNi0wNi0wNS1lbg==/tiny/Vera-Therapeutics.png"/></article></div>

VERA

Vera Therapeutics (Nasdaq: VERA) announced inducement grants under Nasdaq Listing Rule 5635(c)(4). On June 2, 2026, the Compensation Committee granted non-qualified stock options for 28,800 shares and RSUs for 14,150 shares to ten new employees. The options have an exercise price of $31.26 per share. These awards are intended to induce employment in accordance with the company's 2024 Inducement Plan.

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | VERA Stock News